Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Exclusion Criteria

• •1. Positive serological test for IgM anti-HAV antibody, HbsAg, or anti-HCV antibody at screening
• •2. Positive ELISA test for HIV-1 or HIV-2 at screening
• •3. Any of the following abnormal laboratory values at screening: Hemoglobin (Hb) \<12.0g/dL for women and \<13.0g/dL for men, white blood cell count (WBC) \<3,000 cells/mm3, absolute neutrophil count \<1,500 cells/mm3, platelet count \<100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 xULN, INR (International Normalized Ratios for prothrombin time) ≥1.5 xULN
• •4. Any abnormal laboratory values that are considered clinically significant by the Investigator at screening
• •5. QTcF greater than 450 msec for females and 430 msec for males at screening
• •6. History of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome
• •7. History of seizures, epilepsy, cardiovascular, diabetes, or cancer (except basal cell carcinoma)
• •8. History or family history of prolonged QT interval or family history of sudden cardiac death at a young age (\< 30 years )
• •9. History of drug allergy or hypersensitivity, especially to sulfa drugs
• •10. History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use within 6 months prior to first dose of study drug administration
• •11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of a psychiatric illness, or who have any history of suicide attempt or depression
• •12. Anemia or blood/plasma donation within 30 days prior to first dose of study drug administration
• •13. Pregnant or breast-feeding
• •14. Use of tobacco or nicotine-containing products within 30 days prior to first dose of study drug administration
• •15. Use of concomitant medication, including herbal remedies and dietary supplements (except for paracetamol/acetaminophen, ibuprofen, and hormonal contraceptives) within 14 days prior to first dose of study drug administration
• •16. Received any other investigational drug within 30 days prior to first dose of study drug administration
• •1. Any of the following abnormal laboratory values at admission: Hb \<12.0g/dL for women and \<13.0g/dL for men, WBC \<3,000 cells/mm3, absolute neutrophil count \<1,500 cells/mm3, platelet count \<100,000 cells/mm3, serum creatinine ≥ 2 mg/dL, ALT or AST levels ≥ 2 xULN, total bilirubin ≥ 1.5 xULN, INR ≥ 1.5 xULN
• •2. Any abnormal laboratory values that are considered clinically significant by the Investigator at admission
• •3. Any clinically significant abnormality on 12-lead ECG or a QTcF greater than 450 msec for females and 430 msec for males at admission
• •4. Positive urine drug screen or breath alcohol test at admission
• •5. If female, positive serum pregnancy test at admission
• •6. Acute illness within 2 weeks prior to dosing, unless approved by the Sponsor's Medical Monitor